Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZL-82 (Zenitar)
- Development stage
- Preclinical
- Lead developer
- Zenitar
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZL-82 is a small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) being developed by Chengdu Zenitar Biomedical Technology. RIPK1 is a key mediator in the signaling pathways of necroptosis and pro-inflammatory cytokine production. By inhibiting the kinase activity of RIPK1, ZL-82 aims to mitigate necroptotic cell death and neuroinflammation, which are considered significant drivers in the progression of neurodegenerative diseases. Additionally, the drug is being explored for the treatment of inflammatory skin conditions such as atopic dermatitis, where RIPK1-mediated inflammation plays a pathological role.
02
Targets
JAK3 (Janus kinase 3)RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)
Beyond the preview
Go deeper on ZL-82 (Zenitar).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZL-82 (Zenitar).